EP2710000B1 - Composés dihydroisoxazole parasiticides - Google Patents

Composés dihydroisoxazole parasiticides Download PDF

Info

Publication number
EP2710000B1
EP2710000B1 EP20120721146 EP12721146A EP2710000B1 EP 2710000 B1 EP2710000 B1 EP 2710000B1 EP 20120721146 EP20120721146 EP 20120721146 EP 12721146 A EP12721146 A EP 12721146A EP 2710000 B1 EP2710000 B1 EP 2710000B1
Authority
EP
European Patent Office
Prior art keywords
thiophene
trifluoromethyl
dihydro
dihydroisoxazol
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP20120721146
Other languages
German (de)
English (en)
Other versions
EP2710000A1 (fr
Inventor
Zengyun AN
Liang Chen
Shuhui Chen
Jean Marie Defauw
Scott Dale HOLMSTROM
Ping Hu
Chongzhi TANG
William Hunter White
Wentao Wu
Yang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to SI201230196T priority Critical patent/SI2710000T1/sl
Priority to MEP-2015-73A priority patent/ME02113B/me
Priority to PL12721146T priority patent/PL2710000T3/pl
Priority to EP15160519.3A priority patent/EP2918583A1/fr
Publication of EP2710000A1 publication Critical patent/EP2710000A1/fr
Application granted granted Critical
Publication of EP2710000B1 publication Critical patent/EP2710000B1/fr
Priority to HRP20150588TT priority patent/HRP20150588T1/hr
Priority to CY20151100494T priority patent/CY1116450T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Ectoparasites such as fleas, lice, flies, mosquitoes, ticks and mites, as well as endoparasites such as gastrointestinal tract nematodes, flukes, and filarids, are problematic for man and animal alike. Such parasites seriously impact productivity in the domesticated animal industry by reducing weight gain, causing poor quality hide, wool, and meat, and in some cases resulting in death. Ecto- and endoparasites are also responsible, in part, for the spread of disease and discomfort in food and companion animals. Ectoparasites in particular are known to harbor and transmit a variety of microbial pathogens, including bacteria, viruses and protozoan parasites, many of which are pathogenic to humans, other warm-blooded mammals and birds.
  • ectoparasites in which ectoparasites have been implicated include, but are not limited to, malaria, lymphatic- and blood-born filariasis, trachoma, trypanosomiasis, Leishmaniasis, Rocky Mountain Spotted Fever, Lyme Disease, babesiosis, and food-borne illnesses due to Salmonella , E. coli and Campylobacter, for example.
  • ticks parasitize wild as well as domesticated animals and humans, and are known or suspected to be responsible for the transmission of pathogens including bacteria, viruses and protozoan parasites.
  • pathogens including bacteria, viruses and protozoan parasites.
  • ticks are considered to be second in the world to mosquitoes as vectors of human diseases, but they are considered to be the most important vector of pathogens in North America. Effective elimination of tick infestations is difficult and often impractical, due to the need for concomitant treatment of the immediate host as well as the environmental reservoir.
  • tick control is effected by integrated pest management in which different control methods are adapted to one area or against one tick species with due consideration to their environmental effects.
  • Desirable compounds, formulations, and methods would not only provide alternative therapies, but would also overcome one or more of the limitations of current approaches. Such limitations include toxicity and safety of both the animal and the user/owner, limited efficacy ( e . g ., potency and duration), and resistance issues. Also impacting the beneficial use of insecticides and pesticides are administration obstacles, which include mode and recurrence of administration. For example, reducing the frequency of administration while maintaining efficacy is desirable, as excessive and repeated treatment of animals is often inconvenient and/or difficult.
  • Isoxazoline compounds and their uses as insecticide3s and antiparasitic agents are disclosed in WO 2007/079162 , WO 2008/154528 , WO 2010/079077 and WO 2012/038851 .
  • the isoxazoline compounds of each of these disclosures are naphthalene isoxazolines with varying side chains.
  • the present invention encompasses parasiticidal compounds, methods, and formulations for use in and on animals and plants, and which provide alternative options for combating parasiticidal infestations, particularly ectoparasiticidal infestations. Further, certain aspects of the invention overcome at least some limitations in the use of current insecticides and pesticides, particularly in providing effective long term, safe control of parasites.
  • the invention provides a formulation, including a pharmaceutical formulation, comprising a compound or salt of formula I and one or more acceptable carriers.
  • the formulation may further comprise at least one additional active ingredient.
  • a pharmaceutical formulation of the invention may be a human pharmaceutical formulation or a veterinary pharmaceutical formulation.
  • the method may further provide administering at least one other active ingredient to said animal.
  • the animal may be a mammal, and may be a human or a companion animal, for example, a dog or cat.
  • Disclosed is a method for preventing and treating diseases transmitted through parasites comprising administering at least one compound of the invention to an animal in need thereof.
  • the invention provides the use of compounds or salts thereof of formula I for controlling pests.
  • the invention provides a compound or salt of formula I for use in therapy.
  • the invention further provides a compound or salt of formula I for use in controlling ecto- and endoparasite infestations.
  • the invention provides compounds of Formula II, or a salt thereof, of the formula
  • These compounds have utility as intermediates in the processes for preparing certain compounds of Formula I.
  • These Formula II compounds may be chemically modified to result in certain Formula I compounds.
  • the host animal may be a mammal or non-mammal, such as a bird (turkeys, chickens) or fish. Where the host animal is a mammal, it may be a human or non-human mammal.
  • Non-human mammals include domestic animals, such as livestock animals and companion animals. Livestock animals include cattle, camellids, pigs, sheep, goats, and horses. Companion animals include dogs, rabbits, cats, and other pets owned and maintained in close association with humans as part of the human-animal bond.
  • Parasites sometimes also referred to as pests, include both ectoparasites and endoparasites.
  • Ectoparasites include insect and acarine pests which commonly infest or infect animals, and include the egg, larval, pupal, nymphal, and adult stages thereof. Such pests include fleas, lice, mosquitoes, mites, ticks, beetles, and blood-sucking, biting, or nuisance fly species.
  • Endoparasites include nematode pests which commonly infect animals, and include the egg, larval, and adult stages thereof. Such pests include helminths (hookworms, tapeworms, heartworms), and are commercially important because they cause serious diseases in animals, e . g .
  • Typical nematodes are Haemonchus, Trichostrcngyius, Qstertagia, Nematotiirus, Cooperia, Ascaris, Bunostonum, Gesophagostonum, Charbertia, Trichuris, Strongyius, Tr ⁇ chonema, Dictyocaulus, Capsliarsa, Heterakis, Toxocara, Ascaridia, Oxyuris, Ancyiostoma, Uncinaria, Toxascaris and Parascaris.
  • the trematodes include, in particular, the family of Fasciolideae, especially Fasciola hepatica.
  • Controlling refers to either ameliorating or eliminating a current infestation, or preventing an infestation, in or on an animal host or a plant.
  • Effective amount refers to the amount of a compound of formula I, or a salt thereof, sufficient to control an ecto- or endoparasite infestation, and includes causing a measurable reduction in the ecto- or endoparasite infestation population, and as such will depend upon several factors.
  • ranges for a compound of formula I, or a salt thereof, in the methods include from 0.01 to 1000 mg/kg and more desirably, 0.1 to 100 mg/kg of the animal's body weight.
  • the frequency of the administration will also be dependent upon several factors, and can be a single dose administered once a day, once a week, or once a month, for a duration determined by the attending doctor or veterinarian. Additional active ingredients may be administered with a compound of formula I.
  • compositions and formulation components such as carriers includes “veterinarily acceptable”, and thus includes both human and animal applications independently.
  • Salts of the compounds of the invention including pharmaceutically acceptable salts, and common methodology for preparing them, are known in the art. See, e.g., P. Stahl, et al., HANDBOOK OF PHARMACEUTICAL SALTS: PROPERTIES, SELECTION AND USE, (VCHA/Wiley-VCH, 2002 ); S.M. Berge, et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences, Vol. 66, No. 1, January 1977 .
  • the compounds of the invention and their salts may be formulated as pharmaceutical compositions for administration.
  • Such pharmaceutical compositions and processes for making the same are known in the art for both humans and non-human mammals. See, e.g., REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, (A. Gennaro, et al., eds., 19th ed., Mack Publishing Co., 1995 ).
  • Formulations can be administered through various means, including oral administration, parenteral administration such as injection (intramuscular, subcutaneous, intravenous, intraperitoneal) or the like; topical application with or without transdermal penetration such as dipping, spray, bathing, washing, pouring-on and spotting-on, and dusting, or the like.
  • Additional active ingredients may be included in the formulation containing a compound of the invention or a salt thereof.
  • Carrier is used herein to describe any ingredient other than the active component(s) in a formulation.
  • the choice of carrier will to a large extent depend on factors such as the particular mode of administration or application, the effect of the carrier on solubility and stability, and the nature of the dosage form.
  • C 1 -C 5 alkyl refers to straight chain and branched alkyls having one to five carbon atoms, and includes methyl, ethyl, propyl, n-butyl, iso-butyl, pentyl, isopentyl, and neopentyl.
  • C 2 -C 5 alkynyl refers to straight chain and branched alkynyls having two to five carbon atoms, and includes ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 3-methyl-1-butynyl, pentynyl, isopentynyl, and neopentynyl.
  • Halogen or halo refers to fluorine, bromine, chlorine, and iodine.
  • Haloalkyl refers to an alkyl (as noted above) substituted with one or more halo atoms.
  • groups include trifluoromethyl, difluoromethyl, fluoromethyl, methylchloride, dichloromethyl, pentylchloride, butyl chloride, and isopropyl chloride.
  • Cyanoalkyl refers to an alkyl (as noted above) substituted with a cyano group.
  • Alkylthio refers to an alkyl (as noted above) having a sulfur in the group.
  • C 3 -C 6 cycloalkyl refers to cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • C 3 -C 5 cycloheteroalkyl refers to a saturated ring which has 3 to 5 carbons and a hetero atom.
  • the hetero atom may be sulfur, oxygen, nitrogen, or a sulfonyl group.
  • Diseases transmitted through parasites are, for example bacterial, viral, rickettsial and protozoal vector-borne diseases.
  • viral diseases transmitted through arboviruses i.e. arthropod borne viruses
  • Febrile illness Papataci fever, Encephalitis, Meningitis, which are caused by Bunyaviridae such as Bunyavirus, Nairovirus or Phlebovirus
  • Febrile illness, rash, encephalitis, polyarthritis, lymphadenitis which are caused by Togaviridae, such as Sindbisvirus, Chikungunya Virus; tick-borne meningoencephalitis, Dengue hemorhagic fever, encephalitis, Febrile illness, Yellow fever
  • bacterial diseases transmitted through parasites are Rickettsiosis, such as Rocky Mountain spotted fever, tick typhus caused by infection through Rickettsia ssp; Tularemia caused by infection through Francisella tularensis ; Borreliosis or Spirochaetosis, such as Lyme disease, or relapsing fever, caused, by infection through Borrelia ssp.; Ehrllichiosis caused by infection through Ehrlichia ssp.; Plague, caused by infection through Yersinia ssp.
  • Rickettsiosis such as Rocky Mountain spotted fever, tick typhus caused by infection through Rickettsia ssp
  • Tularemia caused by infection through Francisella tularensis
  • Borreliosis or Spirochaetosis such as Lyme disease, or relapsing fever, caused, by infection through Borrelia ssp.
  • Ehrllichiosis caused
  • Examples of protozoal or rickettsial borne diseases are Babesiosis, such as Texas fever, red water disease, Q-fever caused by infection through Babesia ssp .; Theileriosis, such as east coast fever, Mediterranean coast fever, caused by infection through Theileria ssp .; Nagana disease, Sleeping sickness caused by infection through Trypanosoma ssp ., Anaplasmosis caused by infection through Anaplasma ssp .; Malaria caused by infection through Plasmodium ssp .; Leishmaniasis caused by infection through Leishmania ssp.
  • Babesiosis such as Texas fever, red water disease, Q-fever caused by infection through Babesia ssp .
  • Theileriosis such as east coast fever, Mediterranean coast fever, caused by infection through Theileria ssp .
  • Nagana disease Sleeping sickness caused by infection through Trypanosoma ssp .
  • certain of the compounds of the invention are suitable as soil insecticides against pests in the soil, as well as insecticides for plants, such as cereals, cotton, rice, maize, soya, potatoes, vegetables, fruit, tobacco, hops, citrus, and avocados.
  • Certain compounds according to the invention are suitable for protecting plants and plant organs, for increasing the harvest yields, and for improving the quality of the harvested material which are encountered in agriculture, in horticulture, in forests, in gardens, and leisure facilities, and in the protection of stored products and of materials. They may be employed as plant protection agents.
  • Plants are to be understood as meaning in the present context all plants and plant populations such as desired and undesired wild plants or crop plants (including naturally occurring crop plants).
  • Crop plants can be plants which can be obtained by conventional plant breeding and optimization methods or by biotechnological and genetic engineering methods or by combinations of these methods, including the transgenic plants and including the plant cultivars protectable or not protectable by plant breeders' rights.
  • Plant parts are to be understood as meaning all parts and organs of plants above and below the ground, such as shoot, leaf, flower and root, examples which may be mentioned being leaves, needles, stalks, stems, flowers, fruit bodies, fruits, seeds, roots, tubers and rhizomes.
  • the plant parts also include harvested material, and vegetative and generative propagation material, for example cuttings, tubers, rhizomes, offshoots and seeds.
  • Treatment according to the invention of the plants and plant parts with the active compounds is carried out by conventional and known means, including directly acting on, or by allowing the compounds to act on, the surroundings, habitat or storage space by the customary treatment methods, for example by immersion, spraying, evaporation, fogging, scattering, painting on, injection and, in the case of propagation material, in particular in the case of seeds, also by applying one or more coats.
  • the compounds can be converted to the customary formulations, such as solutions, emulsions, wettable powders, water- and oil-based suspensions, powders, dusts, pastes, soluble powders, soluble granules, granules for broadcasting, suspension-emulsion concentrates, natural materials impregnated with active compound, synthetic materials impregnated with active compound, fertilizers and microencapsulations in polymeric substances.
  • customary formulations such as solutions, emulsions, wettable powders, water- and oil-based suspensions, powders, dusts, pastes, soluble powders, soluble granules, granules for broadcasting, suspension-emulsion concentrates, natural materials impregnated with active compound, synthetic materials impregnated with active compound, fertilizers and microencapsulations in polymeric substances.
  • formulations are produced in a known manner, for example by mixing the active compounds with extenders, that is liquid solvents and/or solid carriers, optionally with the use of surfactants, that is emulsifiers and/or dispersants and/or foam-formers.
  • extenders that is liquid solvents and/or solid carriers
  • surfactants that is emulsifiers and/or dispersants and/or foam-formers.
  • the formulations are prepared either in suitable plants or else before or during the application.
  • auxiliaries are substances which are suitable for imparting to the composition itself and/or to preparations derived therefrom (for example spray liquors, seed dressings) particular properties such as certain technical properties and/or also particular biological properties.
  • suitable auxiliaries are extenders, solvents, and carriers.
  • reaction mixture After being detected by TLC and LCMS, the reaction mixture is diluted with dichloromethane, then the solution is washed with water and brine, dried over anhydrous Na 2 SO 4 , filtered, concentrated and the residue is dried in vacuum to give 30 g crude product, which is used directly in next step.
  • reaction mixture After being detected by TLC and LCMS, the reaction mixture is diluted with dichloromethane, then the solution is washed with water and brine, dried over anhydrous Na 2 SO 4 , filtered, concentrated and the residue is dried in vacuum to give 11 g crude product, which is used directly in next step.
  • Compounds may be evaluated against one or more life stages of helminth to measure anthelmintic activity. Compounds may be evaluated at a single concentration followed by serial dilution in order to determine minimal effective concentration. Typically, worms are exposed to compounds in a liquid solution for a predetermined period of time. Activity is measured through one or more variables, which may include an effect on worm motility (e.g., moving versus non-moving) or viability ( e.g., live versus dead).
  • worm motility e.g., moving versus non-moving
  • viability e.g., live versus dead.
  • Compounds may be evaluated against one or more life stages of helminth infestation in an animal to measure in vivo anthelmintic activity. Compounds may be evaluated a single dose, administered on a milligram per kilogram body weight basis, followed by dose titration in order to determine minimal effective point dose.
  • a rodent anthelmintic model for example, adult Mongolian gerbils ( Meriones unguiculates ) infected with one or more species of Strongylid nematode (e.g., Haermonchus contortus and/or Trichostrongylus colubriformis ) are dosed with compounds, administered via oral gavage.
  • Strongylid nematode e.g., Haermonchus contortus and/or Trichostrongylus colubriformis
  • Gerbils are necropsied and gastrointestinal tract worm burden is measured and compared to untreated, infected control gerbils to determine the degree of anthelmintic activity. Similar testing may be conducted in higher species (e.g., dogs, cats, sheep, cattle) whereby nematode burden in treated animals is compared to burden in untreated, infected animals to measure the potency and duration of anthelmintic activity.
  • higher species e.g., dogs, cats, sheep, cattle
  • DMSO dimethylsulfoxide
  • test articles may be conducted using a modified version of the assay as described in Gutierrez et al., J. Med. Entomol. 43(3): 526-532(2006 ).
  • the assay may be modified by using a different tick species (the reference describes Amblyomma americanum ticks) such as Dermacentor variabilis ticks. Further, the reference describes using topical administration, but oral administration may be used.
  • experimental test articles are formulated in a solution of polyethylene glycol-300, propylene glycol and water to the desired concentration, typically 1 - 25 mg/ml, depending on solubility and desired point dose.
  • Tick containment units (comprised of a baby nipple, ventilated screw cap top and reinforcing rubber washer) are attached to the dorsum of adult Sprague-Dawley rats. After attachment of containment units, approximately 10 unfed nymphal stage American dog ticks ( Dermacentor variabilis ) are placed inside of each containment unit. Approximately 24 hours after infestation, test article formulations are administered to rats via oral gavage. Negative control rats receive polyethylene glycol-300, propylene glycol and water alone. Depending on compound availability, a minimum of three (3) and a maximum of five (5) rats are utilized per treatment group. Forty-eight (48) hours post-treatment, containment units are removed and live and dead ticks were counted.
  • Live tick counts are transformed using the natural logarithm transformation plus one (Ln count + 1); addition of one to each count serve to adjust for counts that were zero.
  • Geometric mean (GM) group tick counts are obtained via back-transformation of group mean transformed counts and subtracting one.
  • the non-treated control group is used for comparison to the groups receiving experimental test articles for the calculation of percent efficacy (% reduction in live tick counts).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Claims (15)

  1. Composé, ou un sel de celui-ci, de formule I
    Figure imgb0259
    dans laquelle A est
    Figure imgb0260
    n vaut 0 ou 1 ;
    R1 est un thiényle ou phényle, ledit thiényle ou phényle substitué par 2 ou 3 des atomes d'halogène identiques ou différents ;
    R2 est, à chaque occurrence, indépendamment un hydrogène, alkyle en C1-C5, cycloalkyle en C3-C6 ou halogénoalkyle en C1-C5 ;
    R3 est
    Figure imgb0261
    p vaut indépendamment, à chaque occurrence, 0 ou 1 ;
    R4 est un alkyle en C1-C5, halogénoalkyle en C1-C5, cyanoalkyle en C1-C5, alkylthio en C1-C5, cycloalkyle en C3-C6 éventuellement substitué par un hydroxy, un halogéno ou un alkyle en C1-C5 ; cyclohétéroalkyle en C3-C5 éventuellement substitué par un alkyle en C1-C5, un cycloalkyle en C3-C6 ou un halogénoalkyle en C1-C5 ; phényle, thiényle, pyridinyle, ou
    Figure imgb0262
     dans lequel l'un des atomes de carbone dans lesdits groupes cycloalkyle, indépendamment, ou cyclohétéroalkyle peut former un groupe carbonyle, et dans lequel ledit phényle, thiényle ou pyridinyle est éventuellement substitué par un halogéno ou un groupe carbamoyle ;
    R5 est un hydroxy, -O-(alkyle en C1-C5), ou
    Figure imgb0263
    R6 est un hydrogène, alkyle en C1-C5, halogénoalkyle en C1-C5, cyanoalkyle en C1-C5, alkylthio en C1-C5 ou alcynyle en C2-C5 ;
    ou R2 et R3 se combinent pour former, avec l'atome d'azote auquel ils sont fixés,
    Figure imgb0264
    Y1, Y2 et Y3 sont un carbone ou un azote avec au plus un seul de Y1, Y2 et Y3 étant un azote, et lorsque Y1, Y2 ou Y3 est un carbone, chacun peut être substitué par un alkyle en C1-C5 ;
    R7 est un hydrogène, halogéno, alkyle en C1-C5, ou
    Figure imgb0265
    R8 est un hydroxy, -O-(alkyle en C1-C5), ou
    Figure imgb0266
    R9 est un alkyle en C1-C5,
    Figure imgb0267
     et
    R10 est un hydrogène, alkyle en C1-C5, halogénoalkyle en C1-C5, cyanoalkyle en C1-C5, alkylthio en C1-C5 ou alcynyle en C2-C5.
  2. Composé selon la revendication 1, ou un sel de celui-ci, dans lequel A est
    Figure imgb0268
     et dans lequel R2 est un hydrogène, et n vaut 1.
  3. Composé selon la revendication 1 ou la revendication 2, ou un sel de celui-ci, dans lequel R3 est
    Figure imgb0269
    Figure imgb0270
    Figure imgb0271
    Figure imgb0272
    Figure imgb0273
    Figure imgb0274
  4. Composé selon la revendication 1, ou sel de celui-ci, où A est
    Figure imgb0275
     et dans lequel Y1 est un azote.
  5. Composé selon la revendication 4, ou un sel de celui-ci, dans lequel R7 est
    Figure imgb0276
    Figure imgb0277
    Figure imgb0278
     ou
    Figure imgb0279
  6. Composé selon la revendication 1, ou sel de celui-ci, étant
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-((R)-2-oxopyrrolidin-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le N,N-diméthyl-2-(4-{3-[5-(3,4,5-trichloro-thiophén-2-yl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carbonyl}-pipérazin-1-yl)-acétamide ;
    l'ester méthylique d'acide ({3-[5-(3,5-dichloro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carbonyl}-amino)-acétique ;
    l'ester méthylique d'acide ({3-[5-(3,4,5-trichloro-thiophén-2-yl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carbonyl}-amino)-acétique ;
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-oxo-2-(2,2,2-trifluoroéthylamino)éthyl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(3-oxocyclohexyl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le [2-oxo-1-(2,2,2-trifluoro-éthyl)-pyrrolidin-3-yl]-amide d'acide 3-[5-(3,5-dichloro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carboxylique ;
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-((R)-2-oxopyrrolidin-3-yl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le N-(2-(cyanométhylamino)-2-oxoéthyl)-3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-oxo-2-(prop-2-ynylamino)éthyl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le N-(2-oxo-2-(2,2,2-trifluoroéthylamino)éthyl)-3-(5-(3,4,5-trichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le N-((R)-2-oxopyrrolidin-3-yl)-3-(5-(3,4,5-trichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le N-(2-(cyanométhylamino)-2-oxoéthyl)-3-(5-(3,4,5-trichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le N-(2-oxo-2-(prop-2-ynylamino)éthyl)-3-(5-(3,4,5-trichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-oxo-2-(2,2,2-trifluoroéthylamino)éthyl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-((R)-2-oxopyrrolidin-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le N-(2-(cyanométhylamino)-2-oxoéthyl)-3-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-oxo-2-(prop-2-ynylamino)éthyl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le N-(2-oxo-2-(2,2,2-trifluoroéthylamino)éthyl)-3-(5-(3,4,5-trichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le N-((R)-2-oxopyrrolidin-3-yl)-3-(5-(3,4,5-trichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le N-(2-(cyanométhylamino)-2-oxoéthyl)-3-(5-(3,4,5-trichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le N-(2-oxo-2-(prop-2-ynylamino)éthyl)-3-(5-(3,4,5-trichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le N-(2-oxo-1-(2,2,2-trifluoroéthyl)pyrrolidin-3-yl)-3-(5-(3,4,5-trichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-oxo-2-(2,2,2-trifluoroéthylamino)éthyl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-((R)-2-oxopyrrolidin-3-yl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le N-(2-(cyanométhylamino)-2-oxoéthyl)-3-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-oxo-1-(2,2,2-trifluoroéthyl)pyrrolidin-3-yl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-oxo-2-(prop-2-ynylamino)éthyl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-oxo-2-(2,2,2-trifluoroéthylamino)éthyl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-(éthylamino)-2-oxoéthyl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-((tétrahydrofuran-2-yl)méthyl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-(méthylthio)éthyl)-4,5,6,7-tétrahydro[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(3,3,3-trifluoropropyl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(3-hydroxycyclohexyl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(5-fluoropyridin-2-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(tétrahydro-2H-pyran-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(thiétan-3-yl)-4,5,6,7-tétrahydro[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(tétrahydro-2H-pyran-4-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le N-(1-cyclopropyl-2-oxopyrrolidin-3-yl)-3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le N-(2-oxo-2-(prop-2-ynylamino)éthyl)-3-(5-(3,4,5-trichlorothiophén-2-yl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le N-(2-oxo-1-(2,2,2-trifluoroéthyl)pyrrolidin-3-yl)-3-(5-(3,4,5-trichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le N-(tétrahydro-2H-pyran-4-yl)-3-(5-(3,4,5-trichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le N-(1-cyclopropyl-2-oxopyrrolidin-3-yl)-3-(5-(3,4,5-trichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(4-oxocyclohexyl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-oxo-1-(2,2,2-trifluoroéthyl)pyrrolidin-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(tétrahydro-2H-pyran-4-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le N-(1-cyclopropyl-2-oxopyrrolidin-3-yl)-3-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(4-oxocyclohexyl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-oxo-1-(2,2,2-trifluoroéthyl)pyrrolidin-3-yl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le 3-((R)-5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-((R)-2-oxopyrrolidin-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le 3-((S)-5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-((R)-2-oxopyrrolidin-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le N-(4-carbamoylphényl)-3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le (3-carbamoyl-thiophén-2-yl)-amide d'acide 3-[5-(3,4,5-trichloro-thiophén-2-yl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carboxylique ;
    l'acide 2-(3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamido)acétique ;
    l'acide ({3-[5-(3,4,5-trichloro-thiophén-2-yl)-5-trifluorométhyl-4,5-dihydroisoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carbonyl}-amino)-acétique ;
    le N-(2-(cyanométhylamino)-2-oxoéthyl)-3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-oxo-2-(prop-2-ynylamino)éthyl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le N-(2-(cyanométhylamino)-2-oxoéthyl)-3-(5-(3,4,5-trichlorothiophén-2-yl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carboxamide ;
    le (S)-3-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-oxo-2-(2,2,2-trifluoroéthylamino)éthyl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le [(2,2-difluoro-éthylcarbamoyl)-méthyl]-amide d'acide 3-[5-(3,5-dichloro-4-fluoro-phényl)-5-trifluorométhyl-4,5-dihydroisoxazol-3-yl]-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxylique ;
    le [(2-fluoro-éthylcarbamoyl)-méthyl]-amide d"acide 3-[5-(3,5-dichloro-4-fluoro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxylique ;
    le [(2-fluoro-éthylcarbamoyl)-méthyl]-amide d'acide (S)-3-[5-(3,5-dichloro-4-fluoro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxylique ;
    le 3-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-oxo-2-(prop-2-ynylamino)éthyl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le (S)-3-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-oxo-2-(prop-2-ynylamino)éthyl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide ;
    le 3-(4-chlorobenzo[b]thiophén-2-yl)-5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazole ;
    la 2-[5-(3,5-dichloro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-thiéno[2,3-c]pyridine ;
    la 5-bromo-2-[5-(3,5-dichloro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]thiéno[2,3-b]pyridine ;
    la 2-[5-(3,5-dichloro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-thiéno[2,3-b]pyridine ;
    le 3-(benzo[b]thiophén-2-yl)-5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazole ;
    le 3-(benzo[d]thiazol-2-yl)-5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazole ;
    le 5-(3,5-dichlorophényl)-3-(3-méthylbenzo[b]thiophén-2-yl)-5-(trifluorométhyl)-4,5-dihydroisoxazole ;
    le 5-(3,5-dichlorophényl)-3-(5-méthylbenzo[b]thiophén-2-yl)-5-(trifluorométhyl)-4,5-dihydroisoxazole ;
    le 3-(5-chlorobenzo[b]thiophén-2-yl)-5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazole ;
    le 2-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)thiéno[2,3-b]pyridine-5-carboxylate de méthyle ;
    l'acide 2-[5-(3,5-dichloro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-thiéno[2,3-b]pyridine-5-carboxylique ;
    le 2-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-oxo-2-(2,2,2-trifluoroéthylamino)éthyl)thiéno[2,3-b]pyridine-5-carboxamide ; ou le 2-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-((R)-2-oxopyrrolidin-3-yl)thiéno[2,3-b]pyridine-5-carboxamide.
  7. Composé selon la revendication 1, ou sel de celui-ci, étant le [(2,2-difluoro-éthylcarbamoyl)-méthyl]-amide) d'acide (S)-3-[5-(3,5-dichloro-4-fluoro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxylique.
  8. Composé selon la revendication 1, ou sel de celui-ci, étant le (S)-3-(5-(3,5-dichloro-4-fluorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-N-(2-oxo-2-(prop-2-ynylamino)éthyl)-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxamide.
  9. Composé qui est
    le (1,1-dioxo-thiétan-3-yl)-amide d'acide 3-[5-(3,5-dichloro-phényl)-5-(trifluorométhyl)-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carboxylique ;
    le (1,1-dioxo-hexahydro -1l6-thiopyran-4-yl)-amide d'acide 3-[5-(3,5-dichloro-phényl)-5-(trifluorométhyl)-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carboxylique ;
    le (1,1-dioxo-hexahydro-thiopyran-4-yl)-amide d'acide 3-[5-(3,4,5-trichloro-phényl)-5-(trifluorométhyl)-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carboxylique ;
    le (1,1-dioxo-thiétan-3-yl)-amide d'acide 3-[5-(3,5-dichloro-4-fluoro-phényl)-5-(trifluorométhyl)-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carboxylique ;
    le (1,1-dioxo-hexahydro-thiopyran-4-yl)-amide d'acide 3-[5-(3,5-dichloro-4-fluoro-phényl)-5-(trifluorométhyl)-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carboxylique ;
    ou un sel de celui-ci.
  10. Formulation comprenant un composé, ou sel de celui-ci, selon l'une quelconque des revendications 1 à 9, et un ou plusieurs supports acceptables.
  11. Composé, ou sel de celui-ci, selon l'une quelconque des revendications 1 à 9 destiné à une utilisation dans la lutte contre une infestation parasitaire dans ou sur un animal.
  12. Composé, ou sel de celui-ci, destiné à une utilisation selon la revendication 11, dans lequel ledit animal est un chien ou un chat, et ledit parasite est une tique.
  13. Composé, ou sel de celui-ci, de formule II
    Figure imgb0280
     dans laquelle n vaut 0 ou 1 :
    R1 est un thiényle ou phényle, ledit thiényle ou phényle substitué par 2 ou 3 des atomes d'halogène identiques ou différents ; et
    R11 est un hydroxy, -O-(alkyle en C1-C4), ou un atome d'halogène.
  14. Composé selon la revendication 13, dans lequel il s'agit de
    l'ester méthylique d'acide 3-[5-(3,5-dichloro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carboxylique ;
    l'ester méthylique d'acide 3-[5-(3,5-dichloro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxylique ;
    l'ester méthylique d'acide 3-[5-(3,4,5-trichloro-thiophén-2-yl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carboxylique ;
    l'ester méthylique d'acide 3-[5-(3,5-dichloro-4-fluoro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carboxylique ;
    l'ester méthylique d'acide 3-[5-(3,4,5-trichloro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxylique ;
    l'ester méthylique d'acide 3-[5-(3,5-dichloro-4-fluoro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxylique ;
    l'acide 3-[5-(3,5-dichloro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carboxylique ;
    l'acide 3-[5-(3,5-dichloro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxylique ;
    l'acide 3-[5-(3,4,5-trichloro-thiophén-2-yl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carboxylique ;
    l'acide 3-[5-(3,4,5-trichloro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carboxylique ;
    l'acide 3-[5-(3,5-dichloro-4-fluoro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carboxylique ;
    l'acide 3-[5-(3,5-dichloro-4-fluoro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxylique ;
    l'acide 3-[5-(3,4,5-trichloro-phényl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-5,6-dihydro-4H-cyclopenta[c]thiophène-1-carboxylique ;
    le chlorure de 3-(5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-yl)-4,5,6,7-tétrahydrobenzo[c]thiophène-1-carbonyle ; ou
    le chlorure de 3-[5-(3,4,5-trichloro-thiophén-2-yl)-5-trifluorométhyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tétrahydro-benzo[c]thiophène-1-carbonyle.
  15. Procédé de préparation d'un composé selon la revendication 1, comprenant la réaction d'un composé selon la revendication 13 ou 14, avec un composé de formule
    Figure imgb0281
EP20120721146 2011-05-19 2012-05-08 Composés dihydroisoxazole parasiticides Active EP2710000B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
SI201230196T SI2710000T1 (sl) 2011-05-19 2012-05-08 Parazitocidne spojine dihidroizoksazola
MEP-2015-73A ME02113B (me) 2011-05-19 2012-05-08 Parazitocidni spojevi dihidroizoksazola
PL12721146T PL2710000T3 (pl) 2011-05-19 2012-05-08 Pasożytobójcze pochodne dihydroizoksazolu
EP15160519.3A EP2918583A1 (fr) 2011-05-19 2012-05-08 Composés dihydroisoxazoles antiparasitaires
HRP20150588TT HRP20150588T1 (hr) 2011-05-19 2015-06-02 Parazitocidni spojevi dihidroizoksazola
CY20151100494T CY1116450T1 (el) 2011-05-19 2015-06-04 Παρασιτοκτονες ενωσεις διυδροϊσοξαζολιου

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2011/074294 WO2012155352A1 (fr) 2011-05-19 2011-05-19 Composés de dihydroisoxazole, utilisations antiparasitaires et préparations associées
PCT/CN2012/072878 WO2012155676A1 (fr) 2011-05-19 2012-03-23 Composés parasiticides, procédés et formulations
PCT/US2012/036883 WO2012158396A1 (fr) 2011-05-19 2012-05-08 Composés dihydroisoxazole parasiticides

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP15160519.3A Division EP2918583A1 (fr) 2011-05-19 2012-05-08 Composés dihydroisoxazoles antiparasitaires
EP15160519.3A Division-Into EP2918583A1 (fr) 2011-05-19 2012-05-08 Composés dihydroisoxazoles antiparasitaires

Publications (2)

Publication Number Publication Date
EP2710000A1 EP2710000A1 (fr) 2014-03-26
EP2710000B1 true EP2710000B1 (fr) 2015-04-29

Family

ID=47176150

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20120721146 Active EP2710000B1 (fr) 2011-05-19 2012-05-08 Composés dihydroisoxazole parasiticides
EP15160519.3A Withdrawn EP2918583A1 (fr) 2011-05-19 2012-05-08 Composés dihydroisoxazoles antiparasitaires

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP15160519.3A Withdrawn EP2918583A1 (fr) 2011-05-19 2012-05-08 Composés dihydroisoxazoles antiparasitaires

Country Status (30)

Country Link
US (3) US8648081B2 (fr)
EP (2) EP2710000B1 (fr)
JP (1) JP5989099B2 (fr)
KR (1) KR101586553B1 (fr)
CN (1) CN103547576B (fr)
AR (1) AR086296A1 (fr)
AU (1) AU2012256220B2 (fr)
BR (1) BR112013028132B1 (fr)
CA (1) CA2835436C (fr)
CL (1) CL2013003287A1 (fr)
CO (1) CO6811873A2 (fr)
CR (1) CR20130486A (fr)
CY (1) CY1116450T1 (fr)
DK (1) DK2710000T3 (fr)
EA (1) EA023711B1 (fr)
ES (1) ES2543392T3 (fr)
HK (1) HK1191337A1 (fr)
HR (1) HRP20150588T1 (fr)
IL (1) IL229007A (fr)
ME (1) ME02113B (fr)
MX (1) MX341739B (fr)
PE (1) PE20141041A1 (fr)
PL (1) PL2710000T3 (fr)
PT (1) PT2710000E (fr)
RS (1) RS54048B1 (fr)
SG (1) SG194836A1 (fr)
SI (1) SI2710000T1 (fr)
TW (1) TWI554508B (fr)
UA (1) UA110519C2 (fr)
WO (3) WO2012155352A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY33403A (es) * 2010-06-17 2011-12-30 Novartis Ag Compuestos orgánicos con novedosas isoxazolinas, sus n-óxidos, s-óxidos y sales
WO2012155352A1 (fr) 2011-05-19 2012-11-22 Eli Lilly And Company Composés de dihydroisoxazole, utilisations antiparasitaires et préparations associées
EP2931696B1 (fr) 2012-12-11 2018-08-22 Bracco Imaging S.p.A Procédé continu pour la préparation de l'acide (s)-2-acétyloxypropionique
CA2900029C (fr) 2013-02-06 2021-03-02 Bayer Cropscience Aktiengesellschaft Derives de pyrazole halosubstitues en tant qu'agents phytosanitaires
RU2016131792A (ru) 2014-01-03 2018-02-06 Байер Энимэл Хельс ГмбХ Новые пиразолил-гетероариламиды в качестве средств для борьбы с вредителями
WO2015172099A1 (fr) 2014-05-09 2015-11-12 Kineta, Inc. Composés anti-viraux, compositions pharmaceutiques et méthodes d'utilisation de ceux-ci
CA2949433C (fr) * 2014-06-10 2022-05-03 Bracco Imaging Spa Procede de preparation d'acide (s)-2-acetyloxypropionique et de ses derives
RU2017104717A (ru) 2014-07-15 2018-08-15 Байер Энимэл Хельс ГмбХ Арилтриазолилпиридины в качестве средств для борьбы с вредителями
EP3313400B1 (fr) 2015-06-23 2022-06-15 Intervet International B.V. Solution d'isoxazoline renfermant de la vitamine e et destinée a être utilisée avec de l'eau potable aseptisée
EP3454657B1 (fr) * 2016-05-10 2020-05-13 Elanco Tiergesundheit AG Composé de dihydroisoxazole à utiliser pour lutter contre les poux de mer
EP3532041A4 (fr) * 2016-10-31 2020-06-24 The Scripps Research Institute Méthodes et compositions permettant d'empêcher la transmission de maladies propagées par un vecteur
BR112019015231A2 (pt) 2017-01-25 2020-04-14 Basf Se processos para a preparação de compostos e compostos
WO2018166855A1 (fr) * 2017-03-16 2018-09-20 Basf Se Dihydroisoxazoles à substitution hétérobicyclique
AR113997A1 (es) 2017-12-21 2020-07-08 Intervet Int Bv Composiciones antiparasitarias para unción dorsal continua
AU2019369659A1 (en) * 2018-10-29 2021-04-29 Basf Se Process for preparation of optically enriched aldol compounds
JP2023507322A (ja) 2019-12-20 2023-02-22 ナミ セラピューティクス， インコーポレイテッド がんの処置において有用なＴｏｌｌ様受容体（「ＴＬＲ」）アゴニストプロドラッグを含有する製剤化および／または共製剤化リポソーム組成物ならびにその方法
JP2024511956A (ja) * 2021-03-11 2024-03-18 イン ザ ボウル アニマル ヘルス，インコーポレーテッド 経口のイヌ科動物の飼料およびイヌ科動物におけるダニの侵入を制御する方法
JP2024511957A (ja) * 2021-03-11 2024-03-18 イン ザ ボウル アニマル ヘルス，インコーポレーテッド 経口のイヌ科動物の飼料およびイヌ科動物におけるノミの侵入を制御する方法
CN117412966A (zh) * 2021-06-02 2024-01-16 Fmc公司 用于防治无脊椎有害生物的稠和吡啶
EP4358737A2 (fr) * 2021-06-25 2024-05-01 In the Bowl Animal Health, Inc. Aliment pour félins destiné à être administré par voie orale et procédés de lutte contre les infestations par les puces chez un félin
EP4387451A1 (fr) * 2021-06-25 2024-06-26 In the Bowl Animal Health, Inc. Aliment pour félin destiné à être administré par voie orale et procédés de lutte contre les infestations par les tiques chez un félin
CN114085159B (zh) * 2021-11-25 2023-04-07 浙江大学 一种1,3-环己二酮还原胺化制备3-氨基环己酮的方法
WO2023208447A1 (fr) 2022-04-25 2023-11-02 Basf Se Concentré émulsifiable ayant un système de solvants à base de benzaldéhyde (substitué)
EP4342885A1 (fr) 2022-09-20 2024-03-27 Basf Se Dérivés de n-(3-(aminométhyl)-phényl)-5-(4-phényl)-5-(trifluorométhyl)-4,5-dihydroisoxazol-3-amine et composés similaires en tant que pesticides
EP4389210A1 (fr) 2022-12-21 2024-06-26 Basf Se Composés hétéroaryles pour la lutte contre les nuisibles invertébrés

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1731512T3 (en) * 2004-03-05 2015-01-05 Nissan Chemical Ind Ltd Isoxazoline-substituted benzamide AND INSTRUMENTS FOR COMBATING HARMFUL ORGANISMS
HUP0501170A2 (en) * 2005-12-20 2007-09-28 Richter Gedeon Nyrt 2-heteroaryl-3-phenyl-thieno[2,3-b]pyridines, process for their preparation, their use and pharmaceutical compositions containing them
TWI412322B (zh) * 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
JP2008044880A (ja) * 2006-08-15 2008-02-28 Bayer Cropscience Ag 殺虫性イソオキサゾリン類
MX2009010071A (es) 2007-04-10 2009-10-16 Bayer Cropscience Ag Derivados de aril isoxazolina insecticidas.
AU2008261793A1 (en) * 2007-06-13 2008-12-18 E. I. Du Pont De Nemours And Company Isoxazoline insecticides
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
TWI556741B (zh) 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
CN102088856B (zh) 2008-07-09 2015-11-25 巴斯夫欧洲公司 包含异*唑啉化合物的杀虫活性混合物i
EP2331535B1 (fr) * 2008-09-04 2015-07-22 Syngenta Participations AG Composés insecticides
EP2379544B1 (fr) * 2008-12-18 2013-10-16 Novartis AG Dérivés d'isoxazoline et leur utilisation en tant que pesticide
ES2395704T3 (es) 2008-12-19 2013-02-14 Novartis Ag Derivados de isoxazolina y su uso como pesticida
JP2011098956A (ja) * 2009-10-09 2011-05-19 Sumitomo Chemical Co Ltd イソオキサゾリン化合物及びその用途
WO2011073098A1 (fr) * 2009-12-15 2011-06-23 Bayer Cropscience Ag Acides 1-(hétéroaryl)-pyrazol-4-yl-acétiques, procédés de production et utilisation desdits acides comme herbicides et régulateurs de la croissance des plantes
MX2013001437A (es) 2010-08-05 2013-06-05 Zoetis Llc Derivados de isoxazolina como agentes antiparasitarios.
WO2012038851A1 (fr) * 2010-09-24 2012-03-29 Pfizer Inc. Oximes-isoxazolines utilisés en tant qu'agents antiparasites
RU2013141413A (ru) * 2011-02-10 2015-03-20 Новартис Аг Производные изоксазолина для борьбы с беспозвоночными паразитами
WO2012155352A1 (fr) 2011-05-19 2012-11-22 Eli Lilly And Company Composés de dihydroisoxazole, utilisations antiparasitaires et préparations associées

Also Published As

Publication number Publication date
WO2012158396A1 (fr) 2012-11-22
KR101586553B1 (ko) 2016-01-18
AU2012256220A1 (en) 2013-10-10
IL229007A0 (en) 2013-12-31
CO6811873A2 (es) 2013-12-16
US8648081B2 (en) 2014-02-11
SG194836A1 (en) 2013-12-30
HRP20150588T1 (hr) 2015-07-03
RS54048B1 (en) 2015-10-30
NZ616409A (en) 2015-11-27
AR086296A1 (es) 2013-12-04
US20140107149A1 (en) 2014-04-17
CN103547576A (zh) 2014-01-29
CY1116450T1 (el) 2017-02-08
KR20140002054A (ko) 2014-01-07
CN103547576B (zh) 2016-06-08
WO2012155676A1 (fr) 2012-11-22
ES2543392T3 (es) 2015-08-18
EP2710000A1 (fr) 2014-03-26
MX341739B (es) 2016-08-31
US9255111B2 (en) 2016-02-09
CA2835436C (fr) 2015-12-22
BR112013028132B1 (pt) 2021-05-04
US20150072993A1 (en) 2015-03-12
DK2710000T3 (en) 2015-05-26
WO2012155352A1 (fr) 2012-11-22
SI2710000T1 (sl) 2015-06-30
EP2918583A1 (fr) 2015-09-16
TW201307337A (zh) 2013-02-16
US8889710B2 (en) 2014-11-18
CR20130486A (es) 2014-03-12
IL229007A (en) 2016-07-31
UA110519C2 (uk) 2016-01-12
US20130217699A1 (en) 2013-08-22
CL2013003287A1 (es) 2014-07-25
PE20141041A1 (es) 2014-08-27
EA023711B1 (ru) 2016-07-29
EA201391542A1 (ru) 2014-03-31
JP2014515347A (ja) 2014-06-30
PL2710000T3 (pl) 2015-10-30
JP5989099B2 (ja) 2016-09-07
AU2012256220B2 (en) 2016-12-15
ME02113B (me) 2015-10-20
PT2710000E (pt) 2015-07-06
TWI554508B (zh) 2016-10-21
MX2013013446A (es) 2014-07-14
BR112013028132A2 (pt) 2016-08-09
CA2835436A1 (fr) 2012-11-22
HK1191337A1 (en) 2014-07-25

Similar Documents

Publication Publication Date Title
EP2710000B1 (fr) Composés dihydroisoxazole parasiticides
TWI454472B (zh) 有機化合物
TWI832838B (zh) 新型鄰胺基苯甲醯胺、其作為殺蟲劑的用途及其製備方法
TWI822717B (zh) 吡唑並吡啶類-二醯胺、作為殺蟲劑的用途和其製備方法
CA3164924A1 (fr) Derives d'isoxazoline en tant que pesticides
CN111978260B (zh) 苯并咪唑酮衍生物或农药学上可接受的盐及其用途
KR20240044416A (ko) 이속사졸린 유도체
NZ616409B2 (en) Parasiticidal dihydroisoxazole compounds
KR20240021887A (ko) (thi)옥사졸린 살충제
TW202328126A (zh) 異噁唑啉化合物及其做為害蟲控制劑的用途
CN118234717A (zh) 双环杂芳族化合物及其作为害虫控制剂的用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1191337

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20141124

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 724382

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20150518

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20150588

Country of ref document: HR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012007016

Country of ref document: DE

Effective date: 20150611

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20150588

Country of ref document: HR

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20150528

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20150429

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2543392

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20150818

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20150401169

Country of ref document: GR

Effective date: 20150720

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E010775

Country of ref document: EE

Effective date: 20150702

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E024261

Country of ref document: HU

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1191337

Country of ref document: HK

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 19034

Country of ref document: SK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012007016

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 724382

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150429

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20160201

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 5

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150429

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: ELANCO US INC., US

Free format text: FORMER OWNER: ELI LILLY AND COMPANY, US

REG Reference to a national code

Ref country code: NO

Ref legal event code: CHAD

Owner name: ELANCO US INC., US

REG Reference to a national code

Ref country code: BE

Ref legal event code: FP

Effective date: 20150709

Ref country code: BE

Ref legal event code: PD

Owner name: ELANCO US INC.; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CESSION; FORMER OWNER NAME: ELI LILLY AND COMPANY

Effective date: 20180215

REG Reference to a national code

Ref country code: EE

Ref legal event code: GB1A

Ref document number: E010775

Country of ref document: EE

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: ELANCO US INC.

Effective date: 20180314

REG Reference to a national code

Ref country code: HR

Ref legal event code: PPPP

Ref document number: P20150588

Country of ref document: HR

Owner name: ELANCO US INC., US

REG Reference to a national code

Ref country code: LU

Ref legal event code: PD

Owner name: ELANCO US INC.; US

Free format text: FORMER OWNER: ELI LILLY AND COMPANY

Effective date: 20180214

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20180308 AND 20180314

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: SI

Ref legal event code: SP73

Owner name: ELANCO US INC.; US

Effective date: 20180322

REG Reference to a national code

Ref country code: HU

Ref legal event code: FH1C

Free format text: FORMER REPRESENTATIVE(S): SZENTPETERI ADAM, SBGK SZABADALMI UEGYVIVOEI IRODA, HU

Representative=s name: DR. KOCSOMBA NELLI UEGYVEDI IRODA, HU

Ref country code: HU

Ref legal event code: GB9C

Owner name: ELANCO US INC., US

Free format text: FORMER OWNER(S): ELI LILLY AND COMPANY, US

Ref country code: SK

Ref legal event code: PC4A

Ref document number: E 19034

Country of ref document: SK

Owner name: ELANCO US INC., GREENFIELD, IN, US

Free format text: FORMER OWNER: ELI LILLY AND COMPANY, INDIANAPOLIS, IN, US

Effective date: 20180131

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH

Ref country code: DE

Ref legal event code: R082

Ref document number: 602012007016

Country of ref document: DE

Representative=s name: OFFICE FREYLINGER S.A., LU

Ref country code: DE

Ref legal event code: R081

Ref document number: 602012007016

Country of ref document: DE

Owner name: ELANCO US INC., GREENFIELD, US

Free format text: FORMER OWNER: ELI LILLY AND CO., INDIANAPOLIS, IND., US

REG Reference to a national code

Ref country code: NL

Ref legal event code: PD

Owner name: ELANCO US INC.; US

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT; FORMER OWNER NAME: ELI LILLY AND COMPANY

Effective date: 20180412

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: ELANCO US INC., US

Effective date: 20180613

REG Reference to a national code

Ref country code: AT

Ref legal event code: PC

Ref document number: 724382

Country of ref document: AT

Kind code of ref document: T

Owner name: ELANCO US INC., US

Effective date: 20180625

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20180507

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BG

Payment date: 20190327

Year of fee payment: 8

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20150588

Country of ref document: HR

Payment date: 20190502

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20190430

Year of fee payment: 8

Ref country code: FI

Payment date: 20190425

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20190328

Year of fee payment: 8

Ref country code: EE

Payment date: 20190415

Year of fee payment: 8

Ref country code: LV

Payment date: 20190503

Year of fee payment: 8

Ref country code: HR

Payment date: 20190502

Year of fee payment: 8

Ref country code: MT

Payment date: 20190312

Year of fee payment: 8

Ref country code: RO

Payment date: 20190502

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IS

Payment date: 20190411

Year of fee payment: 8

Ref country code: SK

Payment date: 20190424

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20190424

Year of fee payment: 8

Ref country code: AL

Payment date: 20190425

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190508

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20150588

Country of ref document: HR

Effective date: 20200508

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E010775

Country of ref document: EE

Effective date: 20200531

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20200508

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 19034

Country of ref document: SK

Effective date: 20200508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201130

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201209

Ref country code: HR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200508

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200508

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200531

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200602

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200508

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200508

Ref country code: RS

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200508

Ref country code: LV

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200508

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200509

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20210810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200508

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200508

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240415

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240425

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240411

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240411

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20240430

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240602

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240611

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20240415

Year of fee payment: 13

Ref country code: AT

Payment date: 20240425

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20240426

Year of fee payment: 13

Ref country code: IT

Payment date: 20240514

Year of fee payment: 13

Ref country code: FR

Payment date: 20240415

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240415

Year of fee payment: 13

Ref country code: PT

Payment date: 20240426

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240416

Year of fee payment: 13

Ref country code: SE

Payment date: 20240510

Year of fee payment: 13

Ref country code: HU

Payment date: 20240419

Year of fee payment: 13

Ref country code: BE

Payment date: 20240415

Year of fee payment: 13